RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.
A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
- Chemical Identification
- Environmental Hazards
- First Aid/Medical Treatment
- Handling/Storage/Shipping/Waste Management
- Personal Protection
- Physical Hazards/Corrective Response Actions
- Physical/Chemical Properties
- Report Abstracts and Studies
- Reproductive Risk
- Toxicology/Health Hazards/Exposure
|Example of Acute Exposure data from MEDITEXT.|
RightAnswer Proprietary Data Sources:
Other Government Links Searched via RegsKnowledge:
State Environmental Regulations
Example Content from MEDITEXT for 123318-82-1:
Please note: this is an extract of information from a larger document. Full document and details are available by subscription.
ACUTE EXPOSURE INFORMATION
- WITH THERAPEUTIC USE
- The following adverse effects have been reported: anemia, leukopenia, thrombocytopenia, neutropenia, febrile neutropenia, N/V, diarrhea, abdominal pain, constipation, gingival bleeding, infectious disease, headache, rigor, hepatotoxicity, tachycardia, hypertension, hypotension, fatigue, lethargy, injection site pain, fever, anorexia, arthralgia, back pain, myalgia, dizziness, somnolence, tremor, anxiety, depression, hematuria, cough, dyspnea, epistaxis, contusion, dermatitis, pruritus, erythema, palmar-plantar erythrodysesthesia syndrome, petechiae, flushing. Systemic inflammatory response syndrome or capillary leak syndrome with symptoms of rapid onset respiratory distress, hypotension, pleural effusions, pericardia effusion, and multi-organ failure have been reported in patients.
- WITH POISONING/EXPOSURE
- Overdose data are limited. Effects are expected to be an extension of adverse effects reported with therapeutic use. Grade 4 hyperbilirubinemia, grade 2 and 3 vomiting, and grade 3 maculopapular rash developed in 2 pediatric patients with ALL after receiving clofarabine 70 mg/m(2)/day for 5 days, the highest daily dose administered to a human to date (on a mg/m(2) basis).
© 2011-2020 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.